Prosera
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
- Investigator
- Ali Ataya
- Status
- Accepting Candidates
- Ages
- 18 Years - 75 Years
- Sexes
- All
Hemotag
- Investigator
- Ali Ataya
- Status
- Accepting Candidates
ROR-PH-303 (APD811-303)
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Investigator
- Ali Ataya
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
